KSQ Therapeutics
CAMBRIDGE, MA · Founded 2015 · CIK 0001754052 · Biotech · Private
Computational platform for identifying and validating novel drug targets using machine learning and genomic analysis
ksqtx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $81M
- 1 Form D · Oct 2018
- 96 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 19 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $80,599,985 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2851 | PPI PHARMACEUTICALS, LLC | — | — |
| 2852 | YOLO IMMUNE INC | — | — |
| 2853 | EMPHYMAB BIOTECH, LLC | — | — |
| 2854 | KSQ Therapeutics | — | $81M |
| 2855 | Varigen Biosciences Corporation | — | — |
| 2856 | Kite Pharma, Inc. | — | $79M |
| 2857 | Eyedesis Biosciences, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- DAVID BERRY, M.D., PH.D.Director
- ALAN CRANEDirector
- JAMES GILBERTDirector
- GEORGE GOLUMBESKIDirector
- DAVID MEEKER, M.D.Director · Executive Officer
- RICHARD MOSCICKI, PH.D.Director
- FRANK STEGMEIER, PH.D.Executive Officer
- JOHN TRZUPEK, PH.D.Executive Officer
Patents
- Compositions Of Substituted Pyrazolopyrimidines And Uses Thereofgranted
- NR4A Super-repressors And Methods Of Use Thereofgranted
- Therapeutic Combinations Comprising Ubiquitin- Specific-processing Protease 1 (USP1) Inhibitors And Chemotherapy Agentsapplication
- Gene-regulating Compositions And Methods For Improved Immunotherapyapplication
- Ubiquitin-specific-processing Protease 1 (USP1) Inhibitors For The Treatment Of Solid Tumorsapplication
- Lymphocyte Potency Assayapplication
- Gene-regulating Compositions And Methods For Improved Immunotherapygranted
- Guide Rna Combinations And Methods Of Usegranted
- Methods For Activation And Expansion Of Tumor Infiltrating Lymphocytesapplication
- Gene-regulating Compositions And Methods For Improved Immunotherapygranted
- Gene-regulating Compositions And Methods For Improved Immunotherapygranted
- Uses Of Antagonist, Non-depleting OX40 Antibodiesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.